Article

Identification of Hub Gene and Potential Drugs for Enzalutamide Resistant Castration-Resistant Prostate Cancer Depend On Bioinformatics Analysis

2021-09-01

Abstract excerpt

<h4>Background: </h4> Androgen deprivation therapy (ADT) is still the first line method to treat PCa. However, after a period of therapy, primary PCa will inevitably progress into castration-resistant prostate cancer (CRPC). Enzalutamide (MDV3100) is an androgen receptor (AR) signal inhibitor which can delay the progression of CRPC and increase survival of patients with metastatic CRPC. However, the mechanisms of...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 23746e3e-ebc8-59c3-851e-5951bc56b934
DOI: 10.21203/rs.3.rs-820441/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Identification of Hub Gene and Potential Drugs for Enzalutamide Resistant Castration-Resistant Prostate Cancer Depend On Bioinformatics AnalysisDOI 10.21203/rs.3.rs-820441/v1Read

CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration- resistant prostate cancer by bioinformatic analysisSemantic proximity Read

Bioinformatics and system biology approaches for identifying potential therapeutic targets for prostate cancerSemantic proximity Read

Identification of castration‐resistant prostate cancer‐related hub genes using weighted gene co‐expression network analysisSemantic proximity Read

Bioinformatics analysis identified hub genes in prostate cancer tumorigenesis and metastasisSemantic proximity Read

Identification of key molecules for castration resistance prostate cancer by bioinformatic analysisSemantic proximity Read

Identification of prostate cancer hub genes and therapeutic agents using bioinformatics approachSemantic proximity Read

Comprehensive Analysis of Hub Genes In Prostate CancerSemantic proximity Read

Molecular landscape for risk prediction and personalized therapeutics of castration-resistant prostate cancer: at a glanceSemantic proximity Read

The Identification of Potential Biomarkers and Biological Pathways in Prostate CancerSemantic proximity Read

Identification of UBE2C as hub gene in driving prostate cancer by integrated bioinformatics analysisSemantic proximity Read

ARPC1A correlates with poor prognosis in prostate cancer and is up-regulated by glutamine metabolism to promote tumor cell migration, invasion and cytoskeletal changesSemantic proximity Read

Gene expression profiling analysis of castration-resistant prostate cancer.Semantic proximity Read